These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25318394)

  • 1. Engineered microRNA therapeutics.
    Gibson NW
    J R Coll Physicians Edinb; 2014; 44(3):196-200. PubMed ID: 25318394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-targeting therapeutics for hepatitis C.
    Baek J; Kang S; Min H
    Arch Pharm Res; 2014 Mar; 37(3):299-305. PubMed ID: 24385319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma.
    Young DD; Connelly CM; Grohmann C; Deiters A
    J Am Chem Soc; 2010 Jun; 132(23):7976-81. PubMed ID: 20527935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids.
    Machlin ES; Sarnow P; Sagan SM
    Curr Gene Ther; 2012 Aug; 12(4):301-6. PubMed ID: 22856605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host.
    Thibault PA; Wilson JA
    Pharmacol Res; 2013 Sep; 75():48-59. PubMed ID: 23541631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.
    Gomez IG; Nakagawa N; Duffield JS
    Am J Physiol Renal Physiol; 2016 May; 310(10):F931-44. PubMed ID: 26911854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of small molecule modifiers of microRNAs for the treatment of HCV infection.
    Tripp VT; Young DD
    Methods Mol Biol; 2014; 1103():153-63. PubMed ID: 24318893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.
    Elmén J; Lindow M; Silahtaroglu A; Bak M; Christensen M; Lind-Thomsen A; Hedtjärn M; Hansen JB; Hansen HF; Straarup EM; McCullagh K; Kearney P; Kauppinen S
    Nucleic Acids Res; 2008 Mar; 36(4):1153-62. PubMed ID: 18158304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of microRNA therapeutics is coming of age.
    van Rooij E; Kauppinen S
    EMBO Mol Med; 2014 Jul; 6(7):851-64. PubMed ID: 24935956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Delivery of Anti-microRNA Oligonucleotides in Rats.
    Usa KS; Liu Y; Kurth T; Kriegel AJ; Mattson DL; Cowley AW; Liang M
    Methods Mol Biol; 2017; 1527():409-419. PubMed ID: 28116733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules.
    Thomas M; Deiters A
    Curr Med Chem; 2013; 20(29):3629-40. PubMed ID: 23745562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miRNA Targeting Drugs: The Next Blockbusters?
    Schmidt MF
    Methods Mol Biol; 2017; 1517():3-22. PubMed ID: 27924471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis.
    Gelley F; Zadori G; Nemes B; Fassan M; Lendvai G; Sarvary E; Doros A; Gerlei Z; Nagy P; Schaff Z; Kiss A
    J Gastroenterol Hepatol; 2014 Jan; 29(1):121-7. PubMed ID: 24033414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
    van der Ree MH; van der Meer AJ; de Bruijne J; Maan R; van Vliet A; Welzel TM; Zeuzem S; Lawitz EJ; Rodriguez-Torres M; Kupcova V; Wiercinska-Drapalo A; Hodges MR; Janssen HL; Reesink HW
    Antiviral Res; 2014 Nov; 111():53-9. PubMed ID: 25218783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovering the first microRNA-targeted drug.
    Lindow M; Kauppinen S
    J Cell Biol; 2012 Oct; 199(3):407-12. PubMed ID: 23109665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of microRNA-199a-5p reduces the replication of HCV via regulating the pro-survival pathway.
    Wang H; Gao H; Duan S; Song X
    Virus Res; 2015 Oct; 208():7-12. PubMed ID: 26027911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides.
    Ghosh N; Katare R
    Cardiovasc Diabetol; 2018 Mar; 17(1):43. PubMed ID: 29566757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alterations in microRNA expression patterns in liver diseases].
    Lendvai G; Kiss A; Kovalszky I; Schaff Z
    Orv Hetil; 2010 Nov; 151(45):1843-53. PubMed ID: 20980222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus and human miR-122: insights from the bench to the clinic.
    Wilson JA; Sagan SM
    Curr Opin Virol; 2014 Aug; 7():11-8. PubMed ID: 24721497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.